We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest close session, Eli Lilly (LLY - Free Report) was down 2.48% at $1,152.54. The stock fell short of the S&P 500, which registered a gain of 0.38% for the day. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 0.9%.
Heading into today, shares of the drugmaker had gained 4.65% over the past month, outpacing the Medical sector's gain of 4.34% and the S&P 500's gain of 1.27%.
The investment community will be paying close attention to the earnings performance of Eli Lilly in its upcoming release. The company is slated to reveal its earnings on August 5, 2026. It is anticipated that the company will report an EPS of $8.22, marking a 30.27% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $20.26 billion, indicating a 30.24% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $35.5 per share and revenue of $85.76 billion. These totals would mark changes of +46.63% and +31.58%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.86% fall in the Zacks Consensus EPS estimate. Eli Lilly is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 33.3. This indicates a premium in contrast to its industry's Forward P/E of 15.97.
Also, we should mention that LLY has a PEG ratio of 1.44. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.64 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 229, this industry ranks in the bottom 7% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
In the latest close session, Eli Lilly (LLY - Free Report) was down 2.48% at $1,152.54. The stock fell short of the S&P 500, which registered a gain of 0.38% for the day. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 0.9%.
Heading into today, shares of the drugmaker had gained 4.65% over the past month, outpacing the Medical sector's gain of 4.34% and the S&P 500's gain of 1.27%.
The investment community will be paying close attention to the earnings performance of Eli Lilly in its upcoming release. The company is slated to reveal its earnings on August 5, 2026. It is anticipated that the company will report an EPS of $8.22, marking a 30.27% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $20.26 billion, indicating a 30.24% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $35.5 per share and revenue of $85.76 billion. These totals would mark changes of +46.63% and +31.58%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.86% fall in the Zacks Consensus EPS estimate. Eli Lilly is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 33.3. This indicates a premium in contrast to its industry's Forward P/E of 15.97.
Also, we should mention that LLY has a PEG ratio of 1.44. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.64 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 229, this industry ranks in the bottom 7% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.